GlassScriptPhysician profile
Geraldo A Saavedra
NPI 1700861630
$698,116.49
in general payments reported to CMS, 2019-2025
76 companies · $81K in 2025
The $81K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167K · 2020: $118K · 2021: $92K · 2022: $101K · 2023: $75K · 2024: $64K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Food and Beverage: $30K · Travel and Lodging: $17K · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $173,297.81 |
| Food and Beverage | $29,708.59 |
| Travel and Lodging | $17,161.00 |
| Education | $179.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $365,570.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $129,002.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39,225.14 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $32,816.65 | 2019-2025 | |
| Insulet Corporation | $28,183.52 | 2019-2025 | Omnipod, Omnipod |
| Astrazeneca Pharmaceuticals LP | $21,797.24 | 2019-2025 | Lokelma, Farxiga |
| Mannkind Corporation | $17,460.19 | 2020-2025 | Afrezza |
| Esperion Therapeutics, INC. | $14,733.74 | 2020-2025 | Nexletol |
| Cequr Corporation | $7,831.89 | 2021-2025 | Cequr Simplicity |
| Abbvie INC. | $5,052.53 | 2019-2025 | Linzess, Ubrelvy, Creon |
| Amgen INC. | $4,813.34 | 2019-2025 | Evenity, Repatha, Tepezza |
| Medtronic, INC. | $4,562.96 | 2021-2025 | Minimed 780g, Minimed 770g |
| Corcept Therapeutics | $2,214.42 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $2,197.26 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $2,187.59 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldo Saavedra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.